In prostate cancer, the androgen receptor decreases the expression of miR-29b which targets both TET2 and 5-hmC; 5-hmC represses FOXA1 activity, while its reduction activates the mTOR pathway and AR of prostate cancer [17]. This evidence concerns the gene MTOR and prostate cancer.